中德临床肿瘤学杂志（英文版）2009，Vol.8Issue(5)：296-299,4.DOI:10.1007/s10330-009-0051-5
已被证实用于多药耐药性研究的一种新的多发性骨髓瘤细胞系
A novel myeloma cell line identified for multidrug resistant study
Hui Xiao 1Qi Xiao 2Ke jianZhang 1Xue lanZuo1
作者信息
- 1. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
- 2. Department of Internal Medicine,Yanqiao Hospital of Yunyang Medical College, Shiyan 442000, China
- 折叠
摘要
Abstract
Objective:To find out how to overcome resistance during multiple myeloma (MM) treatment through establishing a multidrug resistant human multiple myeloma cell line and investigating its biological features. Methods:The parent cell line MOLP-2 was exposed to different concentrations of melphalan and a melphalan-resistant cell line MOLP-2/R was identified by continuous stepwise selection. The cell morphology and growth curves were examined. Protein levels of P-gp, MRP and FANCD2 monoubiquitination were checked by Western blotting. The IC50 of melphalan and resistance index (RI) were de-tected by MTT assay. Results:A melphalan-resistant cell line MOLP-2/R was finally identified. The RI of MOLP-2/R cells to melphalan was 6.03. Besides melphalan it was cross resistant to other chemotherapeutic agents, including ADM, CTX, DDP and VP-16. The multiplication time was postponed (P<0.05). Studies showed that FANCD2 protein monoubiquitination was enhanced, but the levels of P-gp and MRP expressions in the MOLP-2/R cells were similar with the parent calls. Conclusion:MOLP-2/R cell line may serve as an ideal model for exploring the mechanism of MDR. Over-expression of FANCD2 protein monoubiquitination might contribute to acquired drug resistance in MOLP-2/R celt line.关键词
multiple myeloma (MM)/FANCD2/drug resistance, multipleKey words
multiple myeloma (MM)/FANCD2/drug resistance, multiple分类
医药卫生引用本文复制引用
Hui Xiao,Qi Xiao,Ke jianZhang,Xue lanZuo..已被证实用于多药耐药性研究的一种新的多发性骨髓瘤细胞系[J].中德临床肿瘤学杂志（英文版）,2009,8(5):296-299,4.
